Study Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Colon Cancer Tissue

Colon Cancer Clinical Trial

Official title:

Phase I Clinical Trial Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Malignant Colon Tissue

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01294072
• Other study ID #: BCC-GI-10 Curcumin
• Status: Recruiting
• Phase: N/A
• Start date: January 2011
• Est. completion date: November 2024

Study information

• Verified date: December 2023
• Source: University of Louisville
• Contact: Gerald W Dryden Jr, MD, Ph.D
• Phone: 502-852-6991
• Email: gerald.dryden[@]louisville.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial will investigate the ability of plant exosomes to more effectively deliver curcumin to normal colon tissue and colon tumors. Curcumin is the yellow pigment of turmeric, a natural product with diverse biological activities. Exosomes are small endosome-derived vesicles (50-100 nanometers [nm] in size). Previous clinical trials conducted with oral curcumin have demonstrated only limited bioavailability even at very high doses of 8-12 grams per day. This trial plans to address this problem of curcumin delivery by using plant exosomes to deliver the drug to colon tumors and normal colon tissue.

Description:

Curcumin is a constituent of the spice turmeric, which is one of the primary ingredients of curry powder. Curcumin has been shown to interfere with colon carcinogenesis in a variety of chemical and genetic rodent models. It has also been shown to have a strong inhibitory effect on the growth of colon cancer cell lines. There is considerable evidence that the effects of curcumin are mediated by changes in signal transduction. There is an extensive body of work showing effects on several signaling pathways, including the beta-catenin and NF-κB pathways. Although curcumin has been viewed as an ideal chemopreventative agent in colon cancer for many years, its application has been impeded by important issues with drug delivery and bioavailability in the reported clinical trials of this compound.

Work from the James Graham Brown Cancer Center published recently suggests that using exosomes as a delivery vehicle leads to overcoming all the major obstacles of using curcumin as an anti-inflammatory agent, including increased stability, solubility, and bioavailability of curcumin. The work was further extended to define the resource that can supply a large quantity of exosomes with a maximum binding capacity of curcumin. Emerging data indicate that exosomes derived from many fruits release exosome-like particles, strongly bind to many hydrophobic drugs including curcumin, and are taken up by the intestine cells as well as the immune cells in the intestine. These results suggest that these fruit-derived exosomes are potentially used as a delivery vehicle to treatment of intestinal diseases. Moreover, both fruit exosomes and curcumin should not generate any side-effects since they are consumed by humans daily.

In this clinical trial, the effect of exosomally delivered curcumin on the immune modulation, cellular metabolism, and phospholipid profile of normal and malignant colon cells in subjects who are undergoing surgery for newly diagnosed colon cancer will be characterized. In selected subjects, the effect of exosomally delivered curcumin on the production of cytokines, the changes of immune cells, and glucose metabolism by administration of 13C-glucose prior to surgical resection will also be characterized.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 35
• Est. completion date: November 2024
• Est. primary completion date: November 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Subjects must have definitive diagnosis of colon cancer.

• Surgical resection of the primary tumor must be an option for the newly diagnosed cancer.

• No history of diabetes

• Subjects must be informed of the investigational nature of this study and sign and give written informed consent in accordance with institutional and federal guidelines.

• Absence of life-limiting medical conditions

• Ability to understand and willingness to sign a written informed consent document.

• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 (Karnofsky > 60%; see Appendix A).

• Subjects must have adequate bone marrow function. ANC > 1000/microliters (microL) and Platelet count >100,000/microL

• Age >20 years

Exclusion Criteria:

• Known familial colon cancer syndrome

• Pregnancy

• Known Human Immunodeficiency Virus (HIV)

• Patients receiving immunosuppressive drugs

• Inflammatory bowel disease

• Active second malignancy in the last 5 years

• Patients receiving any other investigational agent(s)

• Patients who have received any prior chemotherapy or radiation therapy to the primary colon cancer

• Intolerance to grapes, grapefruit, or curcumin

• History of diabetes mellitus

Related Conditions & MeSH terms

• Colon Cancer
• Colonic Neoplasms

Intervention

Dietary Supplement:
• curcumin
tablets-3.6 gram (gm) taken daily for 7 days - 15 subjects
• Curcumin conjugated with plant exosomes
tablets-taken daily for 7 days - 15 subjects

Other:
• No intervention
no treatment

Locations

Country	Name	City	State
United States	University of Louisville Hospital	Louisville	Kentucky

Sponsors (1)

Lead Sponsor	Collaborator
University of Louisville

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concentration of curcumin in normal and cancerous tissue	Concentration of curcumin delivered with curcumin alone or curcumin conjugated with plant exosomes to normal and cancerous colon cells will be compared. This exploratory trial is designed to estimate the effect of a fixed concentration of curcumin when delivered by plant exosomes compared to oral tablets of curcumin alone.	7 days after start of curcumin ingestion
Secondary	safety and tolerability of curcumin alone as determined by adverse events	Curcumin will be taken orally.	7 days after study enrollment
Secondary	effects of curcumin on normal and cancerous colon cells by measuring the biomarkers using histochemical staining		7 days after patient enrollment
Secondary	the immune system response to curcumin, measured by serum cytokine levels		7 days after patient enrollment in study
Secondary	immune response in ex vivo cell cultures of colon cancer cells treated with curcumin and Exo-cur, to be evaluated by using histochemical staining		7 days after patient enrollment in study
Secondary	measurement of curcumin alone on metabolic characteristics of normal colon mucosa and colon tumors		7 days after patient enrollment
Secondary	safety and tolerability of curcumin with plant exosomes as determined by adverse events	Curcumin and plant exosomes will be taken orally.	7 days after study enrollment
Secondary	measurement of curcumin mixed with plant exosomes on metabolic characteristics of normal colon mucosa and colon tumors		7 days after patient enrollment on study